Effect of vitamin D supplementation on cardiovascular outcomes: randomized trials revisited
European Journal of Epidemiology · 22.07.2026
DOI: 10.1007/s10654-026-01438-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Epidemiology, online erschienen am 22.07.2026. Verfasst von Youqing Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsches Krebsforschungszentrum (DKFZ).
Abstract (Originalsprache)
This study aims to estimate the effects of vitamin D supplementation on cardiovascular diseases in populations with different baseline vitamin D distributions, by emulating the VITAL and D-Health trials within the UK Biobank. We emulated randomized trials using subcohorts of the UK Biobank selected to match the inclusion criteria of the VITAL and D-Health trials (n = 237,502 and 185,809, respectively). Exposures were defined as increases in serum 25-hydroxyvitamin-D concentrations of 30 nmol/L and 38 nmol/L, corresponding to the intervention effects in the trials. Outcomes included cardiovascular mortality, myocardial infarction, ischemic stroke, and major adverse cardiovascular events. Expected hazard ratios over trial median follow-up durations of 5.3 and 5.7 years were estimated using Cox proportional hazards models. Vitamin D insufficiency was more common in the UK Biobank than in the original trials. When participants were weighted to match the trial baseline 25-hydroxyvitamin-D distributions, the expected effects became more similar to the largely null findings reported in the original trials. By contrast, among individuals with vitamin D insufficiency or deficiency, increases in 25-hydroxyvitamin-D concentration as achieved in the trials were associated with significantly lower risks of cardiovascular outcomes, except ischemic stroke. For cardiovascular mortality, hazard ratios ranged from 0.74 (95% CI 0.62–0.88) to 0.79 (95% CI 0.69–0.91) across both trial emulations. The largely null findings observed in the trials may partly reflect that the trial populations were predominantly vitamin D-replete. Our emulated trials suggest that substantial cardiovascular benefits from vitamin D supplementation may be expected among populations with low vitamin D status.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
- Faculty of Medicine, University of Heidelberg, 69115, Heidelberg, Germany.
- Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
- Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
- Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. h.brenner@dkfz.de.
- Network Aging Research, University of Heidelberg, 69120, Heidelberg, Germany. h.brenner@dkfz.de.
Förderung
- Deutsches Krebsforschungszentrum (DKFZ)
Zitieren
APA
Wang, Y., Sha, S., Gwenzi, T., Schöttker, B., & Brenner, H. (2026). Effect of vitamin D supplementation on cardiovascular outcomes: randomized trials revisited. European Journal of Epidemiology. https://doi.org/10.1007/s10654-026-01438-7
Vancouver
Wang Y, Sha S, Gwenzi T, Schöttker B, Brenner H. Effect of vitamin D supplementation on cardiovascular outcomes: randomized trials revisited. European Journal of Epidemiology. 2026. doi:10.1007/s10654-026-01438-7
BibTeX
@article{Wang2026,
author = {Wang, Youqing and Sha, Sha and Gwenzi, Tafirenyika and Schöttker, Ben and Brenner, Hermann},
title = {Effect of vitamin D supplementation on cardiovascular outcomes: randomized trials revisited},
journal = {European Journal of Epidemiology},
year = {2026},
doi = {10.1007/s10654-026-01438-7}
}
EUVIMED